SG Americas Securities LLC Decreases Position in The Cooper Companies, Inc. $COO

SG Americas Securities LLC decreased its stake in The Cooper Companies, Inc. (NASDAQ:COO) by 95.8% in the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 15,618 shares of the medical device company’s stock after selling 353,924 shares during the quarter. SG Americas Securities LLC’s holdings in Cooper Companies were worth $1,111,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Geode Capital Management LLC lifted its position in Cooper Companies by 2.5% in the second quarter. Geode Capital Management LLC now owns 5,205,615 shares of the medical device company’s stock worth $368,893,000 after buying an additional 127,907 shares during the last quarter. JPMorgan Chase & Co. raised its stake in shares of Cooper Companies by 3.4% in the first quarter. JPMorgan Chase & Co. now owns 5,177,008 shares of the medical device company’s stock valued at $436,681,000 after acquiring an additional 172,485 shares during the period. Goldman Sachs Group Inc. lifted its holdings in shares of Cooper Companies by 17.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 4,734,327 shares of the medical device company’s stock worth $399,340,000 after acquiring an additional 686,751 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of Cooper Companies by 12.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,954,877 shares of the medical device company’s stock worth $333,595,000 after purchasing an additional 425,400 shares during the period. Finally, Sustainable Growth Advisers LP purchased a new position in shares of Cooper Companies during the 2nd quarter worth about $240,881,000. Institutional investors own 24.39% of the company’s stock.

Analyst Ratings Changes

COO has been the topic of a number of recent analyst reports. Weiss Ratings reissued a “sell (d+)” rating on shares of Cooper Companies in a research report on Wednesday. Stifel Nicolaus cut their target price on Cooper Companies from $90.00 to $85.00 and set a “buy” rating on the stock in a research note on Thursday, August 28th. Robert W. Baird reduced their price target on Cooper Companies from $97.00 to $85.00 and set an “outperform” rating on the stock in a report on Thursday, August 28th. Barclays started coverage on Cooper Companies in a research note on Monday, October 13th. They set an “overweight” rating and a $85.00 price target for the company. Finally, The Goldman Sachs Group set a $64.00 price objective on Cooper Companies and gave the company a “sell” rating in a research report on Wednesday, October 1st. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $84.77.

Cooper Companies Stock Performance

COO stock opened at $75.47 on Friday. The Cooper Companies, Inc. has a 1-year low of $61.78 and a 1-year high of $106.63. The business has a 50-day moving average price of $70.15 and a 200 day moving average price of $71.98. The company has a market capitalization of $15.00 billion, a P/E ratio of 37.18, a PEG ratio of 1.83 and a beta of 1.02. The company has a debt-to-equity ratio of 0.29, a current ratio of 2.12 and a quick ratio of 1.24.

Cooper Companies (NASDAQ:COO) last issued its earnings results on Wednesday, August 27th. The medical device company reported $1.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.07 by $0.03. Cooper Companies had a net margin of 10.08% and a return on equity of 9.82%. The company had revenue of $1.06 billion for the quarter, compared to analysts’ expectations of $1.06 billion. During the same period in the prior year, the business earned $0.96 EPS. The firm’s quarterly revenue was up 5.7% on a year-over-year basis. Cooper Companies has set its Q4 2025 guidance at 1.100-1.140 EPS. FY 2025 guidance at 4.080-4.120 EPS. As a group, equities research analysts forecast that The Cooper Companies, Inc. will post 3.98 EPS for the current fiscal year.

Cooper Companies declared that its Board of Directors has approved a share buyback program on Wednesday, September 17th that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the medical device company to purchase up to 15.4% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s board believes its stock is undervalued.

Insider Buying and Selling

In related news, CEO Albert G. White III purchased 10,000 shares of Cooper Companies stock in a transaction dated Friday, September 5th. The stock was purchased at an average cost of $68.39 per share, with a total value of $683,900.00. Following the transaction, the chief executive officer owned 226,151 shares in the company, valued at approximately $15,466,466.89. The trade was a 4.63% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Gerard H. Warner III acquired 1,450 shares of the firm’s stock in a transaction that occurred on Friday, September 5th. The shares were bought at an average price of $69.23 per share, with a total value of $100,383.50. Following the completion of the purchase, the chief operating officer directly owned 18,319 shares in the company, valued at $1,268,224.37. The trade was a 8.60% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have purchased a total of 17,975 shares of company stock valued at $1,216,346 over the last ninety days. Company insiders own 1.98% of the company’s stock.

Cooper Companies Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.